Showing 5361-5370 of 5771 results for "".
- Market Scope Launches New Website and Entry into Orthopedicshttps://modernod.com/news/market-scope-launches-new-website-and-entry-into-orthopedics/2476168/Market Scope has announced the launch of its new website and the firm’s entry into orthopedics, its second medical vertical. The new
- First Patient Successfully Implanted with Implandata’s Eye Pressure Sensor for Continual Glaucoma Monitoringhttps://modernod.com/news/first-patient-successfully-implanted-with-implandatas-eye-pressure-sensor-for-continual-glaucoma-monitoring/2476170/Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the supr
- Alcon Launches Alcon Retina Fellows Institute to Support Future Leaders of Ophthalmologyhttps://modernod.com/news/alcon-launches-alcon-retina-fellows-institute-to-support-future-leaders-of-ophthalmology/2479630/Alcon announced it is expanding its support of eye care professionals through the launch of a one-of-a-kind training opportunity, the Alcon Retina Fellows Institute. The unique educational offering supports retina fellows during a weekend-long training at the Alcon Experience Center in Fort Worth
- Bayer to Cut 12,000 Jobs, Exit Vet Unit Amid Drag From Suitshttps://modernod.com/news/bayer-to-cut-12000-jobs-exit-vet-unit-amid-drag-from-suits/2479631/Bayer announced Thursday that it will cut around 1,250 jobs from its pharmaceutical division as part of a wider staff-reduction plan that will lead to the loss of about 12,000 positions from its global workforce of 118,200 employees by the end of 2021. The streamlining is part of an overhaul unde
- EyeCare Partners Acquires Holcomb Laser Centerhttps://modernod.com/news/eyecare-partners-acquires-holcomb-laser-center/2479632/EyeCare Partners (ECP) furthered its expansion into the Alabama ophthalmology market with the acquisition of Dr. William Holcomb’s Cullman, Alabama-based Holcomb Laser Center, according to an announcement from EyeCare Partners, as reported in VisionMonday. Terms of the deal were not disclo
- Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usabilityhttps://modernod.com/news/eyenovia-publishes-pg21-phase-2-trial-results-examining-iop-lowering-effect-and-patient-usability/2479637/Eyenovia announced that the full results of its phase 2 PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-
- Lynx Inventory System Now Customized for Retina Specialistshttps://modernod.com/news/lynx-inventory-system-now-customized-for-retina-specialists/2479638/McKesson announced that Lynx, its customizable, cloud-based medication inventory management system for specialty medical practices, has new features designed especially for delivering injectable medication therapies in retina practices. These customizations for retina specialists ensure that each
- New Data Indicate that EyeMax Mono Offers Significant Improvement in Visual Function in Dry AMD Patientshttps://modernod.com/news/new-data-indicate-that-eyemax-mono-offers-significant-improvement-in-visual-function-in-dry-amd-patients/2479640/LEH Pharma announced new data published in the Journal of Refractive Surgery, suggesting that EyeMax Mono offers benefits in terms of visual function for people with dry age-related macular degeneration (AMD). EyeMax Mono is an IOL specifically designed to deliver improved visual outcome
- Genentech Acquires Jecure Therapeuticshttps://modernod.com/news/genentech-acquires-jecure-therapeutics/2479641/Jecure Therapeutics, a biotechnology company with drug discovery programs targeting serious inflammatory diseases, announced a definitive agreement by which it will be acquired by Genentech, the maker of Lucentis (ranibizumab). Terms of the deal were not disclosed. With this acquis
- EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretaryhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-ron-honig-esq-as-svp-general-counsel-company-secretary/2479642/EyePoint Pharmaceuticals announced the appointment of Ron Honig, Esq., as Senior Vice President, general counsel, and company secretary, effective immediately. In this new role, Mr. Honig will the oversee the company’s legal activities, including the legal aspects of licensing, compliance, strate